Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 3/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | PREP | P48147 | 1/20 | 0.31 |
| ▸ | FAP | Q12884 | 1/20 | 0.31 |
| ▸ | F10 | P00742 | 2/20 | 0.30 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.30 |
| ▸ | F2 | P00734 | 2/20 | 0.30 |
| ▸ | MASP2 | O00187 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23165445 | 1.00 | MTNR1A (0.32) | MTNR1AMTNR1BCYP2D6DPP4PREP | |
| SCHEMBL20685675 | 1.00 | MTNR1A (0.32) | MTNR1AMTNR1BCYP2D6DPP4PREP | |
| SCHEMBL23165447 | 1.00 | MTNR1A (0.32) | MTNR1AMTNR1BCYP2D6DPP4PREP | |
| SCHEMBL23346519 | 0.88 | MTNR1A (0.32) | MTNR1AMTNR1BCYP2D6DPP4PREP | |
| SCHEMBL23346565 | 0.86 | MTNR1A (0.32) | MTNR1AMTNR1BDPP4PREPFAP | |
| SCHEMBL22162695 | 0.85 | SMN1; SMN2 (0.31) | — | |
| SCHEMBL20615613 | 0.83 | FUCA1 (0.41) | MTNR1AMTNR1BCYP2D6 | |
| SCHEMBL21973388 | 0.83 | FUCA1 (0.41) | MTNR1AMTNR1BCYP2D6 | |
| SCHEMBL20685673 | 0.81 | MTNR1A (0.33) | MTNR1AMTNR1BDPP4PREPFAP | |
| SCHEMBL22547162 | 0.80 | MTNR1A (0.38) | MTNR1AMTNR1BCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11826357-B2 | Bacterial efflux pump inhibitors | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2023-11-28 | — | — | US | disclosed |
| US-20210137881-A1 | BACTERIAL EFFLUX PUMP INHIBITORS | RUTGERS, THE STATE UNIVERISTY OF NEW JERSEY (US) | 2021-05-13 | — | — | US | disclosed |
| US-20210094912-A1 | INDOLE DERIVATIVES AS EFFLUX PUMP INHIBITORS | RUTGERS, THE STATE UNIVERISTY OF NEW JERSEY (US) | 2021-04-01 | — | — | US | disclosed |
| US-20200325124-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2020-10-15 | — | — | US | disclosed |
| US-20200197382-A1 | BACTERIAL EFFLUX PUMP INHIBITORS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2020-06-25 | — | — | US | disclosed |
| US-20200155507-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2020-05-21 | — | — | US | disclosed |
| US-20190031624-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | UNIV RUTGERS (US) | 2019-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190031624-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | ABCB11, SLC10A1, SLC47A1 | MTNR1A 2287/4885MTNR1B 2010/4885CYP2D6 1059/4885 |
| US-20200325124-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | ABCB11, SLC47A1, SLC47A2 | MTNR1A 2380/4885MTNR1B 2058/4885CYP2D6 1458/4885 |
| US-20210094912-A1 | INDOLE DERIVATIVES AS EFFLUX PUMP INHIBITORS | ABCB11, ABCB1, ABCG2 | MTNR1A 356/4885MTNR1B 343/4885CYP2D6 59/4885 |
| US-20210137881-A1 | BACTERIAL EFFLUX PUMP INHIBITORS | ABCB11, ABCB1, SLC47A1 | MTNR1A 4030/4885MTNR1B 3864/4885CYP2D6 235/4885 |
| US-20200155507-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | ABCB11, SLC10A1, SLC47A1 | MTNR1A 2287/4885MTNR1B 2010/4885CYP2D6 1059/4885 |
| US-20200197382-A1 | BACTERIAL EFFLUX PUMP INHIBITORS | ABCB11, ABCB1, SLC47A1 | MTNR1A 4043/4885MTNR1B 3843/4885CYP2D6 214/4885 |
| US-11826357-B2 | Bacterial efflux pump inhibitors | ABCB11, ABCB1, SLC47A1 | MTNR1A 4043/4885MTNR1B 3843/4885CYP2D6 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.